Saratov JOURNAL of Medical and Scientific Research

Analysis of the regional pharmaceutical market of hypoglycemic drugs of oral administration

Year: 2017, volume 13 Issue: №2 Pages: 225-228
Heading: Parmacology Article type: Original article
Authors: Orlova T.S., Buyuklinskaya O.V.
Organization: Northern State Medical University

Aim: to study the regional pharmaceutical market of oral antidiabetic drugs for 2013-2016 according to the example of the pharmacy network of "Yuniver" (Arkhangelsk), not realizing the program of preferential home. Material and Methods. The study was conducted on the basis of reports on the movement of goods in "Yuniver OOO "for the period from 2013 to 2016 were analyzed range of oral antidiabetic drugs on international nonproprietary names, and trade names, dynamic oral antidiabetic drugs sales (number of dispensed packages). Results. On the basis of data on the movement of goods showed an annual expansion of assortment of oral antidiabetic drugs in the pharmacy network, not realizing the program of preferential home. Conclusion. The assortment of oral hypoglycemic preparations on the example of a pharmacy network that does not realize a program of preferential leave for people with diabetes mellitus testifies to the use of modern medicines that prevent the occurrence of microcirculatory disorders of target organs included in the list of vital and essential drugs and in accordance with clinical recommendations on therapy this pathology.

1. American Diabetes Association: Economic costs of diabetes in the U. S. in 2012. Diabetes Care 2013 Apr; 36 (4): 33-46
2. American Diabetes Association: Standards of medical care in diabetes — 2014. Diabetes Care 2015; 29 (Suppl. 1): 4-42
3. Dedov II, Shestakova MV. The resultsofthe implementation of sub-program "Diabetes" Federal Target Program "Prevention and Control of Social Diseases 2007-2012". Diabetes mellitus 2013; Special: 5-6,10-26, 32-34
4. Dedov II, Shestakova MV, Ametov AS, et al. Initiation and intensification of hypoglycemic therapy in patients with type 2 diabetes: Update Expert Board of the Russian Association of Endocrinologists Consensus. Diabetes mellitus 2015; 1: 5-23
5. Dedov II, Shestakova MV. Algorithms of Specialized Medical Care for Diabetes Mellitus Patients. Diabetes mellitus 2015; 18: 1-112
6. Del Prato S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes, Obesity and Metabolism 2015; 17 (6): 581-590
7. Glinkina IV, Pchelintcev MV, OM Schmidt, et al. Efficacy and safety of the free combination of glimepiride and metformin in patients with type 2 diabetes in clinical practice: Observation program. Effective pharmacotherapy. Endocrinology 2012; 2: 12-16
8. Guariguata L, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice 2014; 103 (2): 137-149
9. Myachina OV, Zuikova AA, Pashkov AN. A study on the state of the load are inhaled buccal epithelial cells in patients with diabetes. Human ecology 2012; 10: 62-64
10. Practice Guidelines for Screening, Diagnosing, and Treating Diabetes, Diabetes Care 2010; 31 (Suppl. 1): 5-11.

2017_02_225-228.pdf375.61 KB

No votes yet